Differential effects of RUNX2 on the androgen receptor in prostate cancer: Synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness

Cancer Research

Volumn 74, Issue 10, 2014, Pages 2857-2868

  Little, Gillian H ^a   Baniwal, Sanjeev K ^a   Adisetiyo, Helty ^a   Groshen, Susan ^a,b   Chimge, Nyam Osor ^a   Kim, Sun Young ^a   Khalid, Omar ^a   Hawes, Debra ^b   Jones, Jeremy O ^c   Pinski, Jacek ^a,b   Schones, Dustin E ^c   Frenkel, Baruch ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SNAIL;

ARTICLE; CANCER RECURRENCE; CELL INVASION; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NKX3 1 GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; SNAI2 GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOPSY; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; COS CELLS; DIHYDROTESTOSTERONE; DOXYCYCLINE; GENE EXPRESSION; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION FACTORS;

EID: 84901284110     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2003     Document Type: Article

References (48)

1. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009;138:245-56.
2. Lin B, Wang J, Hong X, Yan X, Hwang D, Cho JH, et al. Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS ONE 2009;4: e6589.
3. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011;30:2719-33.
4. Tan PY, Chang CW, Chng KR, Wansa KD, Sung WK, Cheung E. Integration of regulatory networks by NKX3-1 promotes androgendependent prostate cancer survival. Mol Cell Biol 2012;32: 399-414.
5. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 2011;30: 3962-76.
6. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007;27: 380-92.
7. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE, et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007; 8:871-8.
8. Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol 2009 23:1203-14.
9. Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, et al. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS ONE 2008;3:e3645.
10. Blyth K,Cameron ER, Neil JC. TheRUNXgenes: gain or loss of function in cancer. Nat Rev Cancer 2005;5:376-87.
11. Ito Y, George FVW, George K. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res 2008;99:33-76.
12. Chimge NO, Frenkel B. TheRUNXfamily in breast cancer: relationships with estrogen signaling. Oncogene 2013;32:2121-30.
13. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89: 755-64.
14. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997;89:765-71.
15. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, et al. Runx2 transcriptional activation of indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008;68: 7795-802.
16. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010;29:811-21.
17. Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, et al. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 2010;9:258.
18. Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, Huser C, et al. Runx2 in normal tissues and cancer cells: A developing story. Blood Cells Mol Dis 2010;45:117-23.
19. Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira Ji, Sakyu T, et al. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci 2010;101:2670-5.
20. Chimge NO, Baniwal S, Little G, Chen Yb, Kahn M, Tripathy D, et al. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res 2011;13: R127.
21. Zhang H, Pan Y, Zheng L, Choe C, Lindgren B, Jensen ED, et al.FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011;71:3257-67.
22. Lim M, Zhong C, Yang S, Bell AM, Cohen MB, Roy-Burman P. Runx2 regulates survivin expression in prostate cancer cells. Lab Invest 2009;90:222-33.
23. Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, et al. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res 2009;15: 4322-35.
24. Yun SJ, Yoon HY, Bae SC, Lee OJ, Choi YH, Moon SK, et al. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer Prostatic Dis 2012;15:369-73.
25. Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, et al. Modulation of Runx2 activity by estrogen receptor-A: implications for osteoporosis and breast cancer. Endocrinology 2008;149: 5984-95.
26. Chimge NO, Baniwal SK, Luo J, Coetzee S, Khalid O, Berman BP, et al. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res 2012; 18:901-11.
27. Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, et al. Regulation of adult bone turnover by sex steroids. J Cell Physiol 2010;224:305-10.
28. Paredes R, Arriagada G, Cruzat F, Villagra A, Olate J, Zaidi K, et al. Bone-specific transcription factor Runx2 interacts with the 1a,25-dihydroxy vitamin D3 receptor to up-regulate rat osteocalcin gene expression in osteoblastic cells. Mol Cell Biol 2004;24:8847-61.
29. Kawate H, Wu Y, Ohnaka K, Takayanagi R. Mutual transactivational repression of Runx2 and the androgen receptor by an impairment of their normal compartmentalization. J Steroid Biochem Mol Biol 2007; 105:46-56.
30. Baniwal SK, Little GH, Chimge NO, Frenkel B. Runx2 controls a feedforward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation. J Cell Physiol 2012;227: 2276-82.
31. McCarthy TL, Chang WZ, Liu Y, Centrella M. Runx2 integrates estrogen activity in osteoblasts. J Biol Chem 2003;278:43121-9.
32. van der Deen M, Akech J, Wang T, FitzGerald TJ, Altieri DC, Languino LR, et al. The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGF-b in prostate cancer cells. J Cell Biochem 2010;109:828-37.
33. Little GH, Noushmehr H, Baniwal SK, Berman BP, Coetzee GA, Frenkel B. Genome-wide Runx2 occupancy in prostate cancer cells suggests a role in regulating secretion. Nucleic Acids Res 2012;40: 3538-47.
34. Zhang Y, Liu T, Meyer C, Eeckhoute J, Johnson D, Bernstein B, et al. Model-based Analysis of ChIP-Seq (MACS). Genome Biol 2008;9: R137.
35. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE,WangZ, et al. Highresolution profiling of histone methylations in the human genome. Cell 2007;129:823-37.
36. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62:6606-14.
37. Thomas MA, Preece DM, Bentel JM. Androgen regulation of the prostatic tumour suppressor NKX3.1 is mediated by its 30 untranslated region. Biochem J 2010;425:575-83.
38. Balbín M, Lopez-Otín C. Hormonal regulation of the human pepsinogen c gene in breast cancer cells. J Biol Chem 1996;27: 15175-81.
39. Wu K, Gore C, Yang L, Fazli L, Gleave M, Pong RC, et al. Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Mol Endocrinol 2012;26:1496-507.
40. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-28.
41. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28:15-33.
42. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003;56: 13-22.
43. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000;60:6111-5.
44. Steffan JJ, Koul HK. Prostate derived ETS factor (PDEF): a putative tumor metastasis suppressor. Cancer Lett 2011;310:109-17.
45. Emadi Baygi M, Soheili ZS, Essmann F, Deezagi A, Engers R, Goering W, et al. Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumor Biol 2010;31:297-307.
46. Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, et al. miR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene 2013;32:296-306.
47. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51.
48. Liu YN, Abou-Kheir W, Yin JJ, Fang L, Hynes P, Casey O, et al. Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor b-initiated prostate cancer epithelial-mesenchymal transition. Mol Cell Biol 2012;32:941-53.